Lysosomal Dysfunction and α-Synuclein Aggregation in Parkinson's Disease: Diagnostic Links

Movement Disorders

Volumn 31, Issue 6, 2016, Pages 791-801

  Moors, Tim ^a   Paciotti, Silvia ^b   Chiasserini, Davide ^b   Calabresi, Paolo ^b,c   Parnetti, Lucilla ^b   Beccari, Tommaso ^b   van de Berg, Wilma D J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF PERUGIA   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Autophagy lysosomal pathway; CSF biomarkers; GBA; Glucocerebrosidase; Lysosomal storage disorders

Indexed keywords

ALPHA LEVO FUCOSIDASE; ALPHA MANNOSIDASE; ALPHA SYNUCLEIN; BETA GALACTOSIDASE; BETA N ACETYLHEXOSAMINIDASE; CATHEPSIN; CATHEPSIN D; GLUCOSYLCERAMIDASE; LYSERGIDE; SPHINGOMYELIN PHOSPHODIESTERASE; BIOLOGICAL MARKER; LYSOSOMAL PROTEINS; PROTEIN;

CELL COUNT; CELL FUNCTION; CELL MIGRATION; CELL ORGANELLE; CELL SIZE; CELL STRUCTURE; CEREBROSPINAL FLUID; ENZYME ACTIVITY; EXOCYTOSIS; GAUCHER DISEASE; GENE MUTATION; GENETIC ASSOCIATION; LYSOSOMAL DYSFUNCTION; LYSOSOME; MACROMOLECULE; MOLECULAR PATHOLOGY; NERVE DEGENERATION; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; REVIEW; HUMAN; LYSOSOME STORAGE DISEASE; METABOLISM;

ALPHA-SYNUCLEIN; BIOMARKERS; HUMANS; LYSOSOMAL STORAGE DISEASES; PARKINSON DISEASE; PROTEINS;

EID: 84971432613     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26562     Document Type: Review

References (137)

1. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997;388(6645):839-840.
2. Braak H, Del TK, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24(2):197-211.
3. Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC. Alpha-synuclein is degraded by both autophagy and the proteasome. J Biol Chem 2003;278(27):25009-25013.
4. Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 2008;372(9645):1263-1271.
5. Schapira AH. Glucocerebrosidase and Parkinson disease: recent advances. Mol Cell Neurosci 2015;66(pt A):37-42.
6. Bae EJ, Yang NY, Lee C, et al. Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and alpha-synuclein aggregation. Exp Mol Med 2015;47:e188.
7. Sardi SP, Clarke J, Kinnecom C, et al. CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc Natl Acad Sci U S A 2011;108(29):12101-12106.
8. Suzuki M, Fujikake N, Takeuchi T, et al. Glucocerebrosidase deficiency accelerates the accumulation of proteinase K-resistant alpha-synuclein and aggravates neurodegeneration in a Drosophila model of Parkinson's disease. Hum Mol Genet 2015;24(23):6675-6686.
9. Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011;146(1):37-52.
10. Parnetti L, Castrioto A, Chiasserini D, et al. Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol 2013;9(3):131-140.
11. Gegg ME, Burke D, Heales SJ, et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol 2012;72(3):455-463.
12. Murphy KE, Gysbers AM, Abbott SK, et al. Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson's disease. Brain 2014;137(pt 3):834-848.
13. Chiasserini D, Paciotti S, Eusebi P, et al. Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies. Mol Neurodegener 2015;10:15.
14. Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis 2009;35(3):385-398.
15. Coutinho MF, Alves S. From rare to common and back again: 60 years of lysosomal dysfunction [published online ahead of print 2015]. Mol Genet Metab 2015. doi: 10.1016/j.ymgme.2015.08.008
16. Saftig P, Klumperman J. Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function. Nat Rev Mol Cell Biol 2009;10(9):623-635.
17. Soldati T, Neyrolles O. Mycobacteria and the intraphagosomal environment: take it with a pinch of salt(s)! Traffic 2012;13(8):1042-1052.
18. Watts C. The endosome-lysosome pathway and information generation in the immune system. Biochim Biophys Acta 2012;1824(1):14-21.
19. Zhao H. Membrane trafficking in osteoblasts and osteoclasts: new avenues for understanding and treating skeletal diseases. Traffic 2012;13(10):1307-1314.
20. de Duve C, Pressman BC, Gianetto R, Wattiaux R, Appelmans F. Tissue fractionation studies. Intracellular distribution patterns of enzymes in rat-liver tissue. Biochem J 1955;60(4):604-617.
21. Mindell JA. Lysosomal acidification mechanisms. Annu Rev Physiol 2012;74:69-86.
22. Finbow ME, Harrison MA. The vacuolar H+-ATPase: a universal proton pump of eukaryotes. Biochem J 1997;324 (pt 3):697-712.
23. Cotter K, Stransky L, McGuire C, Forgac M. Recent Insights into the Structure, Regulation, and Function of the V-ATPases. Trends Biochem Sci 2015;40(10):611-622.
24. Schwake M, Schroder B, Saftig P. Lysosomal membrane proteins and their central role in physiology. Traffic 2013;14(7):739-748.
25. Saftig P, Schroder B, Blanz J. Lysosomal membrane proteins: life between acid and neutral conditions. Biochem Soc Trans 2010;38(6):1420-1423.
26. Schroder BA, Wrocklage C, Hasilik A, Saftig P. The proteome of lysosomes. Proteomics 2010;10(22):4053-4076.
27. Hasilik A, Wrocklage C, Schroder B. Intracellular trafficking of lysosomal proteins and lysosomes. Int J Clin Pharmacol Ther 2009;47(suppl 1):S18-S33.
28. Lefrancois S, Zeng J, Hassan AJ, Canuel M, Morales CR. The lysosomal trafficking of sphingolipid activator proteins (SAPs) is mediated by sortilin. EMBO J 2003;22(24):6430-6437.
29. Wahe A, Kasmapour B, Schmaderer C, et al. Golgi-to-phagosome transport of acid sphingomyelinase and prosaposin is mediated by sortilin. J Cell Sci 2010;123(pt 14):2502-2511.
30. Reczek D, Schwake M, Schroder J, et al. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell 2007;131(4):770-783.
31. Zhao Y, Ren J, Padilla-Parra S, Fry EE, Stuart DI. Lysosome sorting of beta-glucocerebrosidase by LIMP-2 is targeted by the mannose 6-phosphate receptor. Nat Commun 2014;5:4321.
32. Blanz J, Zunke F, Markmann S, et al. Mannose 6-phosphate-independent Lysosomal Sorting of LIMP-2. Traffic 2015;16(10):1127-1136.
33. Lubke T, Lobel P, Sleat DE. Proteomics of the lysosome. Biochim Biophys Acta 2009;1793(4):625-635.
34. Damme M, Suntio T, Saftig P, Eskelinen EL. Autophagy in neuronal cells: general principles and physiological and pathological functions. Acta Neuropathol 2015;129(3):337-362.
35. Pukass K, Goldbaum O, Richter-Landsberg C. Mitochondrial impairment and oxidative stress compromise autophagosomal degradation of alpha-synuclein in oligodendroglial cells. J Neurochem 2015;135(1):194-205.
36. Nixon RA. The role of autophagy in neurodegenerative disease. Nat Med 2013;19(8):983-997.
37. Kaushik S, Cuervo AM. Chaperone-mediated autophagy: a unique way to enter the lysosome world. Trends Cell Biol 2012;22(8):407-417.
38. Li WW, Li J, Bao JK. Microautophagy: lesser-known self-eating. Cell Mol Life Sci 2012;69(7):1125-1136.
39. Klein AD, Futerman AH. Lysosomal storage disorders: old diseases, present and future challenges. Pediatr Endocrinol Rev 2013;11(suppl 1):59-63.
40. Parenti G, Andria G, Ballabio A. Lysosomal storage diseases: from pathophysiology to therapy. Annu Rev Med 2015;66:471-486.
41. Kingma SD, Bodamer OA, Wijburg FA. Epidemiology and diagnosis of lysosomal storage disorders; challenges of screening. Best Pract Res Clin Endocrinol Metab 2015;29(2):145-157.
42. Boustany RM. Lysosomal storage diseases-the horizon expands. Nat Rev Neurol 2013;9(10):583-598.
43. Hoffmann B, Mayatepek E. Neurological manifestations in lysosomal storage disorders - from pathology to first therapeutic possibilities. Neuropediatrics 2005;36(5):285-289.
44. Neudorfer O, Giladi N, Elstein D, et al. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 1996;89(9):691-694.
45. Kluenemann HH, Nutt JG, Davis MY, Bird TD. Parkinsonism syndrome in heterozygotes for Niemann-Pick C1. J Neurol Sci 2013;335(1-2):219-220.
46. Goker-Alpan O, Masdeu JC, Kohn PD, et al. The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow. Brain 2012;135(pt 8):2440-2448.
47. Neudorfer O, Giladi N, Elstein D, et al. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 1996;89(9):691-694.
48. Tayebi N, Walker J, Stubblefield B, et al. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab 2003;79(2):104-109.
49. Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, McInerney-Leo A, Sidransky E. Parkinsonism among Gaucher disease carriers. J Med Genet 2004;41(12):937-940.
50. Bonifati V. Genetics of Parkinson's disease-state of the art, 2013. Parkinsonism Relat Disord 2014;20(suppl 1):S23-S28.
51. Sidransky E, Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurol 2012;11(11):986-998.
52. Lwin A, Orvisky E, Goker-Alpan O, LaMarca ME, Sidransky E. Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab 2004;81(1):70-73.
53. Nichols WC, Pankratz N, Marek DK, et al. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 2009;72(4):310-316.
54. Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009;132(pt 7):1783-1794.
55. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009;361(17):1651-1661.
56. Liu J, Zhang HX. Significant study of population stratification, sensitivity analysis and trim and fill analyses on GBA mutation and Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 2014;165B(1):96-102.
57. Mao X, Wang T, Peng R, et al. Mutations in GBA and risk of Parkinson's disease: a meta-analysis based on 25 case-control studies. Neurol Res 2013;35(8):873-878.
58. Goker-Alpan O, Stubblefield BK, Giasson BI, Sidransky E. Glucocerebrosidase is present in alpha-synuclein inclusions in Lewy body disorders. Acta Neuropathol 2010;120(5):641-649.
59. Choi JH, Stubblefield B, Cookson MR, et al. Aggregation of alpha-synuclein in brain samples from subjects with glucocerebrosidase mutations. Mol Genet Metab 2011;104(1-2):185-188.
60. Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009;132(pt 7):1783-1794.
61. Shachar T, Lo BC, Recchia A, Wiessner C, Raas-Rothschild A, Futerman AH. Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond. Mov Disord 2011;26(9):1593-1604.
62. Deng H, Xiu X, Jankovic J. Genetic convergence of Parkinson's disease and lysosomal storage disorders. Mol Neurobiol 2015;51(3):1554-1568.
63. Volders P, Van HJ, Lories RJ, et al. Niemann-Pick disease type B: an unusual clinical presentation with multiple vertebral fractures. Am J Med Genet 2002;109(1):42-51.
64. Gan-Or Z, Ozelius LJ, Bar-Shira A, et al. The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease. Neurology 2013;80(17):1606-1610.
65. Dagan E, Schlesinger I, Ayoub M, et al. The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews. Parkinsonism Relat Disord 2015;21(9):1067-1071.
66. Foo JN, Liany H, Bei JX, et al. Rare lysosomal enzyme gene SMPD1 variant (p.R591C) associates with Parkinson's disease. Neurobiol Aging 2013;34(12):2890-2895.
67. Clark LN, Chan R, Cheng R, et al. Gene-wise association of variants in four lysosomal storage disorder genes in neuropathologically confirmed Lewy body disease. PLoS ONE 2015;10(5):e0125204.
68. Winder-Rhodes SE, Garcia-Reitbock P, Ban M, et al. Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome. Mov Disord 2012;27(2):312-315.
69. Tofaris GK. Lysosome-dependent pathways as a unifying theme in Parkinson's disease. Mov Disord 2012;27(11):1364-1369.
70. Roze E, Paschke E, Lopez N, et al. Dystonia and parkinsonism in GM1 type 3 gangliosidosis. Mov Disord 2005;20(10):1366-1369.
71. Muthane U, Chickabasaviah Y, Kaneski C, et al. Clinical features of adult GM1 gangliosidosis: report of three Indian patients and review of 40 cases. Mov Disord 2004;19(11):1334-1341.
72. Yoshida K, Oshima A, Sakuraba H, et al. GM1 gangliosidosis in adults: clinical and molecular analysis of 16 Japanese patients. Ann Neurol 1992;31(3):328-332.
73. Inzelberg R, Korczyn AD. Parkinsonism in adult-onset GM2 gangliosidosis. Mov Disord 1994;9(3):375-377.
74. Argov Z, Navon R. Clinical and genetic variations in the syndrome of adult GM2 gangliosidosis resulting from hexosaminidase A deficiency. Ann Neurol 1984;16(1):14-20.
75. Buechner S, De Cristofaro MT, Ramat S, Borsini W. Parkinsonism and Anderson Fabry's disease: a case report. Mov Disord 2006;21(1):103-107.
76. Ramirez A, Heimbach A, Grundemann J, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006;38(10):1184-1191.
77. Anglade P, Vyas S, Javoy-Agid F, et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson';s disease. Histol Histopathol 1997;12(1):25-31.
78. Alvarez-Erviti L, Rodriguez-Oroz MC, Cooper JM, et al. Chaperone-mediated autophagy markers in Parkinson disease brains. Arch Neurol 2010;67(12):1464-1472.
79. Dehay B, Bove J, Rodriguez-Muela N, et al. Pathogenic lysosomal depletion in Parkinson's disease. J Neurosci 2010;30(37):12535-12544.
80. Tanji K, Mori F, Kakita A, Takahashi H, Wakabayashi K. Alteration of autophagosomal proteins (LC3, GABARAP and GATE-16) in Lewy body disease. Neurobiol Dis 2011;43(3):690-697.
81. Murphy KE, Gysbers AM, Abbott SK, et al. Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease. Mov Disord 2015;30(12):1639-1647.
82. Kurzawa-Akanbi M, Hanson PS, Blain PG, et al. Glucocerebrosidase mutations alter the endoplasmic reticulum and lysosomes in Lewy body disease. J Neurochem 2012;123(2):298-309.
83. Gegg ME, Burke D, Heales SJ, et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol 2012;72(3):455-463.
84. Alcalay RN, Levy OA, Waters CC, et al. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain 2015;138(pt 9):2648-2658.
85. Platt FM. Sphingolipid lysosomal storage disorders. Nature 2014;510(7503):68-75.
86. Abbott SK, Li H, Munoz SS, et al. Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease. Mov Disord 2014;29(4):518-526.
87. Gegg ME, Sweet L, Wang BH, Shihabuddin LS, Sardi SP, Schapira AH. No evidence for substrate accumulation in Parkinson brains with GBA mutations. Mov Disord 2015;30(8):1085-1089.
88. Dehay B, Martinez-Vicente M, Caldwell GA, et al. Lysosomal impairment in Parkinson's disease. Mov Disord 2013;28(6):725-732.
89. Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC. Alpha-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem 2003;278(27):25009-25013.
90. Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L. Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J Biol Chem 2008;283(35):23542-23556.
91. Mak SK, McCormack AL, Manning-Bog AB, Cuervo AM, Di Monte DA. Lysosomal degradation of alpha-synuclein in vivo. J Biol Chem 2010;285(18):13621-13629.
92. Tenreiro S, Reimao-Pinto MM, Antas P, et al. Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's disease. PLoS Genet 2014;10(5):e1004302.
93. Martinez-Vicente M, Talloczy Z, Kaushik S, et al. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest 2008;118(2):777-788.
94. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004;305(5688):1292-1295.
95. Tanik SA, Schultheiss CE, Volpicelli-Daley LA, Brunden KR, Lee VM. Lewy body-like alpha-synuclein aggregates resist degradation and impair macroautophagy. J Biol Chem 2013;288(21):15194-15210.
96. Martinez-Vicente M, Cuervo AM. Autophagy and neurodegeneration: when the cleaning crew goes on strike. Lancet Neurol 2007;6(4):352-361.
97. Ebrahimi-Fakhari D, Wahlster L, McLean PJ. Protein degradation pathways in Parkinson's disease: curse or blessing. Acta Neuropathol 2012;124(2):153-172.
98. Xilouri M, Brekk OR, Stefanis L. Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies. Mov Disord. 2016.
99. Bae EJ, Yang NY, Song M, et al. Glucocerebrosidase depletion enhances cell-to-cell transmission of alpha-synuclein. Nat Commun 2014;5:4755.
100. Yap TL, Gruschus JM, Velayati A, et al. Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J Biol Chem 2011;286(32):28080-28088.
101. Yap TL, Velayati A, Sidransky E, Lee JC. Membrane-bound alpha-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. Mol Genet Metab 2013;108(1):56-64.
102. Rothaug M, Zunke F, Mazzulli JR, et al. LIMP-2 expression is critical for beta-glucocerebrosidase activity and alpha-synuclein clearance. Proc Natl Acad Sci U S A 2014;111(43):15573-15578.
103. Yap TL, Gruschus JM, Velayati A, Sidransky E, Lee JC. Saposin C protects glucocerebrosidase against alpha-synuclein inhibition. Biochemistry 2013;52(41):7161-7163.
104. Cullen V, Lindfors M, Ng J, et al. Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. Mol Brain 2009;2:5.
105. Qiao L, Hamamichi S, Caldwell KA, et al. Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol Brain 2008;1:17.
106. Sevlever D, Jiang P, Yen SH. Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. Biochemistry 2008;47(36):9678-9687.
107. Takahashi M, Ko LW, Kulathingal J, Jiang P, Sevlever D, Yen SH. Oxidative stress-induced phosphorylation, degradation and aggregation of alpha-synuclein are linked to upregulated CK2 and cathepsin D. Eur J Neurosci 2007;26(4):863-874.
108. Bae EJ, Yang NY, Lee C, Kim S, Lee HJ, Lee SJ. Haploinsufficiency of cathepsin D leads to lysosomal dysfunction and promotes cell-to-cell transmission of alpha-synuclein aggregates. Cell Death Dis 2015;6:e1901.
109. Yelamanchili SV, Chaudhuri AD, Flynn CT, Fox HS. Upregulation of cathepsin D in the caudate nucleus of primates with experimental parkinsonism. Mol Neurodegener 2011;6:52.
110. McNeill A, Magalhaes J, Shen C, et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 2014;137(pt 5):1481-1495.
111. McGlinchey RP, Lee JC. Cysteine cathepsins are essential in lysosomal degradation of alpha-synuclein. Proc Natl Acad Sci U S A 2015;112(30):9322-9327.
112. Rodriguez A, Webster P, Ortego J, Andrews NW. Lysosomes behave as Ca2+-regulated exocytic vesicles in fibroblasts and epithelial cells. J Cell Biol 1997;137(1):93-104.
113. Andrews NW. Regulated secretion of conventional lysosomes. Trends Cell Biol 2000;10(8):316-321.
114. Jaiswal JK, Andrews NW, Simon SM. Membrane proximal lysosomes are the major vesicles responsible for calcium-dependent exocytosis in nonsecretory cells. J Cell Biol 2002;159(4):625-635.
115. Tam C, Idone V, Devlin C, et al. Exocytosis of acid sphingomyelinase by wounded cells promotes endocytosis and plasma membrane repair. J Cell Biol 2010;189(6):1027-1038.
116. Muhle C, Huttner HB, Walter S, et al. Characterization of acid sphingomyelinase activity in human cerebrospinal fluid. PLoS One 2013;8(5):e62912.
117. Fonteh AN, Ormseth C, Chiang J, Cipolla M, Arakaki X, Harrington MG. Sphingolipid metabolism correlates with cerebrospinal fluid Beta amyloid levels in Alzheimer's disease. PloS one 2015;10(5):e0125597.
118. Goi G, Fabi A, Lombardo A, et al. Stability of enzymes of lysosomal origin in human cerebrospinal fluid. Clin Chim Acta 1987;163(2):215-224.
119. Persichetti E, Chiasserini D, Parnetti L, et al. Factors influencing the measurement of lysosomal enzymes activity in human cerebrospinal fluid. PLoS ONE 2014;9(7):e101453.
120. Guldbrandsen A, Vethe H, Farag Y, et al. In-depth characterization of the cerebrospinal fluid (CSF) proteome displayed through the CSF proteome resource (CSF-PR). Mol Cell Proteomics 2014;13(11):3152-3163.
121. Palmieri M, Impey S, Kang H, et al. Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways. Hum Mol Genet 2011;20(19):3852-3866.
122. Hineno T, Sano A, Kondoh K, Ueno S, Kakimoto Y, Yoshida K. Secretion of sphingolipid hydrolase activator precursor, prosaposin. Biochem Biophys Res Commun 1991;176(2):668-674.
123. Lachenal G, Pernet-Gallay K, Chivet M, et al. Release of exosomes from differentiated neurons and its regulation by synaptic glutamatergic activity. Mol Cell Neurosci 2011;46(2):409-418.
124. Antonucci F, Turola E, Riganti L, et al. Microvesicles released from microglia stimulate synaptic activity via enhanced sphingolipid metabolism. EMBO J 2012;31(5):1231-1240.
125. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol 2002;2(8):569-579.
126. Schneider A, Simons M. Exosomes: vesicular carriers for intercellular communication in neurodegenerative disorders. Cell Tissue Res 2013;352(1):33-47.
127. Chiasserini D, van Weering JR, Piersma SR, et al. Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset. J Proteomics 2014;106:191-204.
128. Goetzl EJ, Boxer A, Schwartz JB, et al. Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease. Neurology 2015;85(1):40-47.
129. Zhang L, Sheng R, Qin Z. The lysosome and neurodegenerative diseases. Acta Biochim Biophys Sin (Shanghai) 2009;41(6):437-445.
130. Jimenez-Jimenez FJ, Alonso-Navarro H, Garcia-Martin E, Agundez JA. Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease. Front Cell Neurosci 2014;8:369.
131. Omar R, Pappolla M, Argani I, Davis K. Acid phosphatase activity in senile plaques and cerebrospinal fluid of patients with Alzheimer's disease. Arch Pathol Lab Med 1993;117(2):166-169.
132. Schwagerl AL, Mohan PS, Cataldo AM, Vonsattel JP, Kowall NW, Nixon RA. Elevated levels of the endosomal-lysosomal proteinase cathepsin D in cerebrospinal fluid in Alzheimer disease. J Neurochem 1995;64(1):443-446.
133. Sundelof J, Sundstrom J, Hansson O, et al. Higher cathepsin B levels in plasma in Alzheimer's disease compared to healthy controls. J Alzheimers Dis 2010;22(4):1223-1230.
134. Armstrong A, Mattsson N, Appelqvist H, et al. Lysosomal network proteins as potential novel CSF biomarkers for Alzheimer's disease. Neuromolecular Med 2014;16(1):150-160.
135. Balducci C, Pierguidi L, Persichetti E, et al. Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease. Mov Disord 2007;22(10):1481-1484.
136. van Dijk KD, Persichetti E, Chiasserini D, et al. Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's disease. Mov Disord 2013;28(6):747-754.
137. Parnetti L, Chiasserini D, Persichetti E, et al. Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. Mov Disord 2014;29(8):1019-1027.